Halozyme
HALO
175 hedge funds and large institutions have $1.32B invested in Halozyme in 2015 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 66 increasing their positions, 51 reducing their positions, and 13 closing their positions.
154% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 13
39% more call options, than puts
Call options by funds: $22.9M | Put options by funds: $16.4M
29% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 51
11% more funds holding
Funds holding: 158 → 175 (+17)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
40% less capital invested
Capital invested by funds: $2.2B → $1.32B (-$884M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$27.3M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$17.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.5M |
| 4 |
JP Morgan Chase
New York
|
+$7.37M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$6.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$48.9M |
| 2 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$29.7M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$16.2M |
| 4 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$12.8M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$5.27M |
HALO Hedge Fund Activity: Q3 2015 in Review
175 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q3 2015, worth a combined $1.32B — down 40% from $2.2B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new HALO positions and 13 closed out — a net gain of 20 holders — while 66 added to existing stakes and 51 trimmed.
The largest buyer was Invesco, adding an estimated $27.3M. The largest seller was Millennium Management, cutting an estimated $48.9M.
- 175 institutional investors held Halozyme (HALO) as of Q3 2015, up from 158 in Q2 2015.
- Funds reported $1.32B of Halozyme stock for Q3 2015, down 40% quarter-over-quarter.
- 33 funds opened new Halozyme positions in Q3 2015 and 13 closed out, a net change of +20 holders.
- The largest Halozyme buyer in Q3 2015 was Invesco, an estimated $27.3M added.
- The largest Halozyme seller in Q3 2015 was Millennium Management, an estimated $48.9M sold.
Based on aggregated 13F filings for Q3 2015.